Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 5.3% - Here's Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report)'s share price dropped 5.3% during mid-day trading on Monday . The company traded as low as $20.50 and last traded at $20.46. Approximately 6,827 shares traded hands during mid-day trading, a decline of 97% from the average daily volume of 241,203 shares. The stock had previously closed at $21.60.

Wall Street Analyst Weigh In

DNTH has been the topic of a number of recent analyst reports. TD Cowen initiated coverage on shares of Dianthus Therapeutics in a research note on Friday, December 20th. They issued a "buy" rating on the stock. Raymond James upgraded shares of Dianthus Therapeutics to a "moderate buy" rating in a research note on Thursday, December 12th. Oppenheimer upped their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an "outperform" rating in a research note on Monday, November 11th. Finally, HC Wainwright restated a "buy" rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, Dianthus Therapeutics currently has a consensus rating of "Buy" and an average price target of $46.83.

Dianthus Therapeutics Trading Up 3.3 %

The business's 50-day moving average is $22.53 and its two-hundred day moving average is $25.12. The firm has a market cap of $696.12 million, a P/E ratio of -9.41 and a beta of 1.82.

Remove Ads

Institutional Investors Weigh In On Dianthus Therapeutics

A number of institutional investors have recently modified their holdings of the business. Woodline Partners LP grew its position in Dianthus Therapeutics by 20.0% in the 4th quarter. Woodline Partners LP now owns 300,504 shares of the company's stock worth $6,551,000 after purchasing an additional 50,000 shares during the last quarter. Vestal Point Capital LP grew its position in Dianthus Therapeutics by 172.2% in the 4th quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company's stock worth $23,435,000 after purchasing an additional 680,000 shares during the last quarter. Octagon Capital Advisors LP grew its position in Dianthus Therapeutics by 20.8% in the 4th quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company's stock worth $46,002,000 after purchasing an additional 363,500 shares during the last quarter. Millennium Management LLC grew its position in Dianthus Therapeutics by 160.2% in the 4th quarter. Millennium Management LLC now owns 90,436 shares of the company's stock worth $1,972,000 after purchasing an additional 55,682 shares during the last quarter. Finally, Janus Henderson Group PLC grew its position in Dianthus Therapeutics by 14.4% in the 4th quarter. Janus Henderson Group PLC now owns 1,085,648 shares of the company's stock worth $23,607,000 after purchasing an additional 136,314 shares during the last quarter. Institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.